Annette Sauter

2.7k citations

23 papers · 594 indexed · h-index 12

Co-authors: Volkmar Braun Susanne Mahren Harold Koendgen S. Peter Howard Ludwig Kappos Amit Bar‐Or Xavier Montalbán Stephen L. Hauser
Topics: Multiple Sclerosis Research Studies (13 papers)Peripheral Neuropathies and Disorders (4 papers)Bacterial Genetics and Biotechnology (4 papers)
Cited by: Pathology and Forensic Medicine Neurology Psychiatry and Mental health
Journals: SHILAP Revista de lepidopterologíaNeurology The Lancet Neurology
Partner nations: Switzerland United States Germany

In The Last Decade

Annette Sauter

23 papers receiving 584 citations

Peers

Countries citing papers authored by Annette Sauter

Since Specialization

Citations

This map shows the geographic impact of Annette Sauter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annette Sauter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annette Sauter more than expected).

Fields of papers citing papers by Annette Sauter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annette Sauter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annette Sauter. The network helps show where Annette Sauter may publish in the future.

Co-authorship network of co-authors of Annette Sauter

This figure shows the co-authorship network connecting the top 25 collaborators of Annette Sauter. A scholar is included among the top collaborators of Annette Sauter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annette Sauter. Annette Sauter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension 2023 ·Journal of Neurology ·Ludwig Kappos,Anthony Traboulsee,David K.B. Li,Amit Bar‐Or,Frederik Barkhof,Xavier Montalbán,David Leppert,(unknown),Hans‐Martin Schneble,Harold Koendgen,Annette Sauter,Qing Wang,Stephen L. Hauser	10
2	Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials 2023 ·EBioMedicine ·Amit Bar‐Or,(unknown),Christopher Harp,Corrado Bernasconi,Leo H. Bonati,Anne H. Cross,Saloumeh K Fischer,Laura Gaetano,Stephen L. Hauser,Robert L. Hendricks,Ludwig Kappos,Jens Kühle,David Leppert,Fabian Model,Annette Sauter,Harold Koendgen,Xiaoming Jia,Ann Herman	46
3	031 Long-term efficacy of ocrelizumab in primary progressive multiple sclerosis: 6.5-study years 2022 ·Journal of Neurology Neurosurgery & Psychiatry ·Klaus Schmierer,Jerry S. Wolinsky,Bruno Brochet,Hans‐Peter Hartung,Robert T. Naismith,Harold Koendgen,Marianna Manfrini,Annette Sauter,(unknown),Ludwig Kappos	1
4	COVID-19 in ocrelizumab-treated people with multiple sclerosis 2020 ·Multiple Sclerosis and Related Disorders ·Richard A. Hughes,(unknown),(unknown),Hans‐Martin Schneble,Erwan Muros‐Le Rouzic,Annette Sauter,Licínio Craveiro,Paul Dillon,(unknown),(unknown),(unknown),Harold Koendgen	54
5	Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO Trials (2420) 2020 ·Neurology ·Amit Bar‐Or,(unknown),Christopher Harp,Anne Cross,(unknown),Stephen L. Hauser,Xiaoming Jia,Ludwig Kappos,Harold Koendgen,Jens Kühle,David Leppert,Marianna Manfrini,Fabian Model,Annette Sauter,(unknown)	1
6	Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial 2020 ·The Lancet Neurology ·Jerry S. Wolinsky,Douglas L. Arnold,Bruno Brochet,Hans-Peter Hartung,Xavier Montalbán,Robert T. Naismith,Marianna Manfrini,James Overell,Harold Koendgen,Annette Sauter,(unknown),Stanislas Hubeaux,Ludwig Kappos,Stephen L. Hauser	103
7	Serum Ig Levels and Risk of Serious Infections by Baseline Ig Quartile in the Pivotal Phase III Trials and Open-Label Extensions of Ocrelizumab in Multiple Sclerosis (1173) 2020 ·Neurology ·Amit Bar‐Or,Robert Bermel,Martin S. Weber,Richard A. Hughes,(unknown),Jianmei Wang,Annette Sauter,Harold Koendgen,Licínio Craveiro,Stephen L. Hauser,Tobias Derfuß	7
8	Clinically Meaningful Decline on SDMT Primarily Occurs Independently of Relapses and Is Slowed by Ocrelizumab in Patients with Multiple Sclerosis: Results from the Pooled OPERA Studies (1290) 2020 ·Neurology ·Ralph H. B. Benedict,J. de Sèze,Stephen L. Hauser,Hans‐Peter Hartung,Ludwig Kappos,James Overell,Harold Koendgen,(unknown),Annette Sauter,Marianna Manfrini,Stanley Cohan	1
9	Assessment of Drug–Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials 2019 ·Clinical Pharmacokinetics ·Katrijn Bogman,Jochen Brumm,Carsten Hofmann,(unknown),Markus Niggli,(unknown),Annette Sauter,(unknown),(unknown),Christophe Schmitt	2
10	Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis 2019 ·Neurology ·Frederik Barkhof,Ludwig Kappos,Jerry S. Wolinsky,David K.B. Li,Amit Bar‐Or,Hans‐Peter Hartung,Shibeshih Belachew,Jian Han,Laura Julián,Annette Sauter,Julie Napieralski,Harold Koendgen,Stephen L. Hauser	39
11	Efficacy of ocrelizumab in patients with PPMS with and without T1 gadolinium-enhancing lesions at baseline in a Phase III, placebo-controlled trial 2016 ·mediaTUM (Technical University of Munich) ·J. S. Wolinsky,Douglas L. Arnold,Amit Bar‐Or,J. de Sèze,Gavin Giovannoni,Bernhard Hemmer,(unknown),Annette Sauter,Donna Masterman,Paulo Fontoura,Hideki Garren,P Chin,Xavier Montalbán	4
12	Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study 2015 ·mediaTUM (Technical University of Munich) ·Xavier Montalbán,Bernhard Hemmer,Kottil Rammohan,Gavin Giovannoni,J. de Sèze,Amit Bar‐Or,Douglas L. Arnold,Annette Sauter,Algirdas Kakarieka,Donna Masterman,P Chin,Hideki Garren,Jerry S. Wolinsky,(unknown)	36
13	Baseline Demographics and Disease Characteristics from ORATORIO, a Phase III Trial Evaluating Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis (P7.017) 2015 ·Neurology ·Xavier Montalbán,Bernhard Hemmer,Kottil Rammohan,Gavin Giovannoni,J. de Sèze,Amit Bar‐Or,Douglas L. Arnold,Annette Sauter,David Leppert,Peter Chin,Hideki Garren,Jerry S. Wolinsky	2
14	Week 144 Results of a Phase II, Randomized, Multicenter Trial Assessing the Safety and Efficacy of Ocrelizumab in Patients with Relapsing–Remitting Multiple Sclerosis (RRMS) (S31.004) 2013 ·Neurology ·Stephen L. Hauser,David Li,Peter A. Calabresi,Paul O’Connor,Amit Bar‐Or,Frederik Barkhof,Annette Sauter,David Leppert,Donna Masterman,(unknown),Ludwig Kappos	9
15	Gene Regulation by Transmembrane Signaling 2006 ·BioMetals ·Volkmar Braun,Susanne Mahren,Annette Sauter	57
16	Gene Regulation by Transmembrane Signaling 2005 ·BioMetals ·Volkmar Braun,Susanne Mahren,Annette Sauter	12
17	Defined Inactive FecA Derivatives Mutated in Functional Domains of the Outer Membrane Transport and Signaling Protein of Escherichia coli K-12 2004 ·Journal of Bacteriology ·Annette Sauter,Volkmar Braun	23
18	In Vivo Evidence for TonB Dimerization 2003 ·Journal of Bacteriology ·Annette Sauter,S. Peter Howard,Volkmar Braun	52
19	The Disability Assessment for Dementia Scale: A 12-Month Study of Functional Ability in Mild to Moderate Severity Alzheimer Disease 2001 ·Alzheimer Disease & Associated Disorders ·Howard Feldman,Annette Sauter,A. Donald,Isabelle Gélinas,Serge Gauthier,(unknown),Wim Parys,(unknown)	94
20	Xenotransplantation - eine Studie des TAB 2001 ·SHILAP Revista de lepidopterología ·Annette Sauter	2

About Annette Sauter

Annette Sauter is a scholar working on Pathology and Forensic Medicine, Neurology and Oncology, having authored 23 papers that have together received 594 indexed citations. Recurring topics across this work include Multiple Sclerosis Research Studies (13 papers), Peripheral Neuropathies and Disorders (4 papers) and Bacterial Genetics and Biotechnology (4 papers). The work is most often cited by research in Pathology and Forensic Medicine (303 citations), Neurology (150 citations) and Psychiatry and Mental health (79 citations). Annette Sauter has collaborated with scholars based in Switzerland, United States and Germany. Frequent co-authors include Volkmar Braun, Susanne Mahren, Harold Koendgen, S. Peter Howard, Ludwig Kappos, Amit Bar‐Or, Xavier Montalbán, Stephen L. Hauser, Jerry S. Wolinsky and Howard Feldman. Their work appears in journals such as SHILAP Revista de lepidopterología, Neurology and The Lancet Neurology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact